PGNX - プロジェニックス・ファ―マシュ―ティカルズ (Progenics Pharmaceuticals Inc.) プロジェニックス・ファ―マシュ―ティカルズ

 PGNXのチャート


 PGNXの企業情報

symbol PGNx
会社名 Progenics Pharmaceuticals Inc. (プロジェニックス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 プロジェニックス・ファーマシューティカルズ(Progenics Pharmaceuticals Inc.)は癌の標的と治療のための医薬品及びその他の製品の開発に従事する。同社のパイプラインには、癌を標的とする治療薬(AZEDRA及び1095)、前立腺癌(1404及びPyL)治療用前立腺特異的膜抗原(PSMA)標的造影剤、及び画像解析ツールを含む。また、オピオイド誘発性便秘治療用の商業製品であるRELISTOR(臭化メチルナルトレキソン)を含む。AZEDRAは、悪性及び/または再発性褐色細胞腫、及びパラガングリオーマ(副腎と副腎の外側にそれぞれ見られる希少腫瘍)の治療薬として開発されている放射線治療製品候補である。RELISTORは、オピオイド誘発性便秘の治療薬である。PyLは、前立腺癌治療用の臨床病期のフッ素化PSMA標的陽電子放出断層撮影(PET)イメージング剤である。PSMA TTCは、トリウム-227標識PSMA標的抗体治療剤である。   プロジェニックス・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。おもに腫瘍学の薬の開発を行う。前立腺特異的膜抗原(PSMA)や、前立腺癌細胞の表面上、および多数の他の固形腫瘍の新生血管に見られるタンパク質に焦点を当て研究開発を行う。前立腺癌のための製品候補PSMA ADCと 1404(trofolastat)を手掛ける。   Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.
本社所在地 One World Trade Center 47th Floor New York NY 10007 USA
代表者氏名 Peter J. Crowley ピーター・J・クローリー
代表者役職名 Independent Chairman of the Board
電話番号 +1 646-975-2500
設立年月日 31747
市場名 NASDAQ National Market System
ipoyear 1997年
従業員数 64人
url http://www.progenics.com/
nasdaq_url https://www.nasdaq.com/symbol/pgnx
adr_tso
EBITDA EBITDA(百万ドル) -53.17600
終値(lastsale) 5.93
時価総額(marketcap) 500789211.6
時価総額 時価総額(百万ドル) 477.94450
売上高 売上高(百万ドル) 13.65300
企業価値(EV) 企業価値(EV)(百万ドル) 438.09850
当期純利益 当期純利益(百万ドル) -50.31300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Progenics Pharmaceuticals Inc. revenues increased 38% to $7.1M. Net loss decreased 13% to $28.6M. Revenues reflect Royalty income increase of 40% to $6.6M License revenue increase of 28% to $463K. Lower net loss reflects Research_Development decrease of 21% to $16.5M (expense) Change in contingent consideration liabi decrease of 19% to $2.1M (expense) Interest (expense) income.

 PGNXのテクニカル分析


 PGNXのニュース

   Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update  2020/05/07 11:30:00 GlobeNewswire
Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and…
   Velan Capital Agrees to Support Merger of Lantheus and Progenics  2020/04/14 13:00:00 Business Wire
NORTH BILLERICA, Mass. & NEW YORK--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that Lantheus has enter
   Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger  2020/04/02 12:30:00 Business Wire
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that they have decided to reschedu
   The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion  2020/02/21 12:46:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arcus Biosciences Inc (NYSE: RCUS ) BELLUS Health Inc (NASDAQ: BLU ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Masimo Corporation (NASDAQ: MASI ) (announced its fourth-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Relmada Therapeutics Inc (NASDAQ: RLMD ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced $287.5-million debt offering) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Feb. 13) Scpharmaceuticals Inc (NASDAQ: SCPH ) Soligenix, Inc.
   Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review  2020/01/21 21:15:00 GlobeNewswire
NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing…
   Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update  2020/05/07 11:30:00 GlobeNewswire
Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and…
   Velan Capital Agrees to Support Merger of Lantheus and Progenics  2020/04/14 13:00:00 Business Wire
NORTH BILLERICA, Mass. & NEW YORK--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that Lantheus has enter
   Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger  2020/04/02 12:30:00 Business Wire
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that they have decided to reschedu
   The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion  2020/02/21 12:46:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arcus Biosciences Inc (NYSE: RCUS ) BELLUS Health Inc (NASDAQ: BLU ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Masimo Corporation (NASDAQ: MASI ) (announced its fourth-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Relmada Therapeutics Inc (NASDAQ: RLMD ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced $287.5-million debt offering) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Feb. 13) Scpharmaceuticals Inc (NASDAQ: SCPH ) Soligenix, Inc.
   Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review  2020/01/21 21:15:00 GlobeNewswire
NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing…
   Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update  2020/05/07 11:30:00 GlobeNewswire
Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and…
   Velan Capital Agrees to Support Merger of Lantheus and Progenics  2020/04/14 13:00:00 Business Wire
NORTH BILLERICA, Mass. & NEW YORK--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that Lantheus has enter
   Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger  2020/04/02 12:30:00 Business Wire
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that they have decided to reschedu
   The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion  2020/02/21 12:46:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arcus Biosciences Inc (NYSE: RCUS ) BELLUS Health Inc (NASDAQ: BLU ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Masimo Corporation (NASDAQ: MASI ) (announced its fourth-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Relmada Therapeutics Inc (NASDAQ: RLMD ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced $287.5-million debt offering) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Feb. 13) Scpharmaceuticals Inc (NASDAQ: SCPH ) Soligenix, Inc.
   Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review  2020/01/21 21:15:00 GlobeNewswire
NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 プロジェニックス・ファ―マシュ―ティカルズ PGNX Progenics Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)